The value of research collaborations and consortia in rare cancers
The value of research collaborations and consortia in rare cancers
复制标题
DOI：
10.1016/s1470-2045(15)00388-5
复制
发表时间：
2016-02-01
期刊：
影响因子：
51.1
通讯作者：
Ray-Coquard, Isabelle
中科院分区：
文献类型：
--
作者：
Blay, Jean-Yves;Coindre, Jean-Michel;Ray-Coquard, Isabelle
罕见癌症的定义是每年每10万人中发病率低于6例。它们约占所有人类癌症的20%，并且与所谓的常见肿瘤相比，生存率更差，因为准确诊断的延迟，治疗不足以及参与临床试验的机会较少（因为缺乏来自学术和工业赞助商的专门试验）。在本系列论文中，我们讨论了研究联盟如何应对这些挑战，并建议将这些联盟与参考网络整合，这些参考网络聚集了多学科专家中心，用于管理罕见肿瘤。
Rare cancers are defined by an incidence of less than six per 100 000 people per year. They represent roughly 20% of all human cancers and are associated with worse survival than are so-called frequent tumours, because of delays to accurate diagnosis, inadequate treatments, and fewer opportunities to participate in clinical trials (because of a paucity of dedicated trials from both academic and industrial sponsors). In this Series paper, we discuss how these challenges can be addressed by research consortia and suggest the integration of these consortia with reference networks, which gather multidisciplinary expert centres, for management of rare tumours.